Antibe Therapeutics (ATE) News Today → Forget the “Magnificent 7” Tech Companies, Buy This AI Stock Instead (From Banyan Hill Publishing) (Ad) Free ATE Stock Alerts C$0.30 0.00 (0.00%) (As of 05/10/2024) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider Trades All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative April 9, 2024 | finance.yahoo.comCanadian Investment Regulatory Organization Trading Halt - ATEMarch 4, 2024 | finance.yahoo.comAntibe Announces Unfavorable Decision in Arbitration With Nuance PharmaFebruary 9, 2024 | marketbeat.comAntibe Therapeutics (TSE:ATE) Share Price Passes Above 50-Day Moving Average of $0.92Antibe Therapeutics (TSE:ATE) Stock Price Crosses Above 50-Day Moving Average of $0.92February 1, 2024 | finance.yahoo.comAntibe Extends Early Warrant Exercise Incentive ProgramDecember 31, 2023 | morningstar.comAntibe Therapeutics Inc ATEDecember 29, 2023 | finance.yahoo.comAntibe Announces Early Warrant Exercise Incentive ProgramNovember 13, 2023 | finance.yahoo.comAntibe Reports Q2 2024 Interim Financial and Operating ResultsNovember 8, 2023 | theglobeandmail.comAntibe Therapeutics: Top 25 Performing Stocks Year-to-Date on Toronto Stock Exchange (ATE)November 6, 2023 | baystreet.caHercules at 52-Week High on Barrick HookupNovember 1, 2023 | baystreet.caAntibe at 52-Week High on NewsNovember 1, 2023 | finance.yahoo.comAntibe Completes First Clinical Study of Otenaproxesul’s New FormulationOctober 18, 2023 | benzinga.comAntibe Initiates First Clinical Study of Otenaproxesul's New FormulationSeptember 28, 2023 | ca.finance.yahoo.comStocks in play: Antibe Therapeutics Inc.September 28, 2023 | finance.yahoo.comAntibe Receives Approval to Initiate PK/PD Study of OtenaproxesulSeptember 6, 2023 | investing.comAntibe Therapeutics Inc. (ATE)August 21, 2023 | finance.yahoo.comToronto Stock Exchange, Antibe Therapeutics Inc., View From The C-SuiteAugust 21, 2023 | finance.yahoo.comToronto Stock Exchange, Antibe Therapeutics Inc., View From The C-SuiteAugust 17, 2023 | theglobeandmail.comClosing Bell: Antibe Therapeutics Inc down on Wednesday (ATE)June 30, 2023 | finance.yahoo.comAntibe Therapeutics Inc.'s (TSE:ATE) Path To ProfitabilityJune 23, 2023 | baystreet.caLast Week of June Looks EventfulJune 16, 2023 | travel.usnews.comBest Times To Visit AntibesJune 13, 2023 | theglobeandmail.comClosing Bell: Antibe Therapeutics Inc up on Monday (ATE)June 3, 2023 | theglobeandmail.comClosing Bell: Antibe Therapeutics Inc down on Friday (ATE)May 19, 2023 | theglobeandmail.comClosing Bell: Antibe Therapeutics Inc up on Thursday (ATE)April 28, 2023 | theglobeandmail.comClosing Bell: Antibe Therapeutics Inc flat on Thursday (ATE)April 25, 2023 | finance.yahoo.comAntibe’s Chief Medical Officer to Present at the 2023 Precision in Clinical Trials SummitApril 18, 2023 | theglobeandmail.comClosing Bell: Antibe Therapeutics Inc up on Tuesday (ATE)April 18, 2023 | finance.yahoo.comAntibe to Present at the 2023 Bloom Burton & Co. Healthcare Investor ConferenceApril 17, 2023 | theglobeandmail.comClosing Bell: Antibe Therapeutics Inc down on Monday (ATE)April 14, 2023 | theglobeandmail.comClosing Bell: Antibe Therapeutics Inc flat on Friday (ATE)April 11, 2023 | finance.yahoo.comAntibe Provides April 2023 Corporate UpdateApril 11, 2023 | theglobeandmail.comClosing Bell: Antibe Therapeutics Inc flat on Monday (ATE)April 7, 2023 | theglobeandmail.comClosing Bell: Antibe Therapeutics Inc down on Thursday (ATE)February 15, 2023 | finance.yahoo.comAntibe Reports Q3 2023 Interim Financial and Operating ResultsFebruary 5, 2023 | theglobeandmail.comAntibe Therapeutics: Top 25 Undervalued Toronto Stock Exchange Stocks (ATE)November 15, 2022 | finance.yahoo.comAntibe Reports Q2 2023 Interim Financial and Operating ResultsNovember 2, 2022 | finance.yahoo.comAntibe Closes Previously Announced Strategic Sale of Citagenix SubsidiaryNovember 1, 2022 | theglobeandmail.comAntibe Therapeutics: Top 10 Undervalued Medical Devices & Instruments Industry Stocks (ATE)September 15, 2022 | theglobeandmail.comAntibe Therapeutics: Bottom 25 Performing Stocks Year-to-Date on TSE (ATE)September 12, 2022 | theglobeandmail.comAntibe Therapeutics: Stocks trading at Less Than Cash Value on (ATE)September 7, 2022 | finance.yahoo.comATE.TO: Plans on Track for Acute Pain Program for Otenaproxesul…August 18, 2022 | theglobeandmail.comAntibe Therapeutics: Bottom 25 Performing Stocks Year-to-Date on Toronto Stock Exchange (ATE)August 2, 2022 | theglobeandmail.comAntibe Therapeutics Inc stock advanced on Friday.June 15, 2022 | nz.finance.yahoo.comAntibe Therapeutics Announces Amendment to Warrant TermsJune 3, 2022 | finance.yahoo.comAntibe Therapeutics Inc. (ATE.TO)May 2, 2022 | finance.yahoo.comAntibe Therapeutics Announces Strategic Sale of Citagenix SubsidiaryFebruary 16, 2022 | msn.comATE.TO: First Human PK/PD Studies Underway in Otenaproxesul’s Post-Operative Pain Program…February 16, 2022 | finance.yahoo.comATE.TO: First Human PK/PD Studies Underway in Otenaproxesul’s Post-Operative Pain Program…January 2, 2022 | marketbeat.comAntibe Therapeutics Inc. (TSE:ATE) Given Consensus Rating of "Buy" by AnalystsShares of Antibe Therapeutics Inc. (TSE:ATE) have received an average recommendation of "Buy" from the six research firms that are currently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company.December 27, 2021 | finance.yahoo.comIs There An Opportunity With Antibe Therapeutics Inc.'s (TSE:ATE) 23% Undervaluation? Get Antibe Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATE and its competitors with MarketBeat's FREE daily newsletter. Email Address The Crypto 9-5 Escape Plan (Ad)A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market. Click here to get instant access to the guide ATE Media Mentions By Week ATE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATE News Sentiment▼0.000.56▲Average Medical News Sentiment ATE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATE Articles This Week▼00▲ATE Articles Average Week Get Antibe Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Sirona Biochem News Resverlogix News Kane Biotech News Aeterna Zentaris News Ceapro News Covalon Technologies News Innovotech News Aptose Biosciences News Quest PharmaTech News IBEX Technologies News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (TSE:ATE) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersForget the “Magnificent 7” Tech Companies, Buy This AI Stock InsteadBanyan Hill PublishingWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsThe Crypto 9-5 Escape PlanCrypto 101 MediaThe A.I. story nobody is telling you (Read ASAP)TradeSmithBuy this small stock before coming AI Tidal WaveChaikin AnalyticsElon’s New Device is About to Shock the WorldInvestorPlaceCharles Payne Demystifies OptionsUnstoppable ProsperityRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap Sniper Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Antibe Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
